Skip to main content

Intercure Ltd.

corporate_fare Company Profile

Intercure Ltd.

INCR·NASDAQ·Healthcare·CIK 0001857030

InterCure Ltd. is an Israeli public corporation incorporated in November 1994. The company is a pioneer in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use, primarily through its subsidiary Canndoc. For over 18 years, InterCure has been a leader in the licensed production and distribution of cannabis and cannabis-based products throughout Israel, one of the first countries to establish a government-sanctioned regime for medical cannabis. The company owns all issued and outstanding shares of Canndoc, Pharmazone, Leon Pharm, and Cannolam, along with other holdings in additional pharmacies and trade houses. InterCure's shares are traded on the Nasdaq under the symbol "INCR" and on the TASE under the symbol "INCR". Its principal executive offices are located at 85 Medinat ha Yehudim Street, 4676670 Israel.

Intercure Ltd. (NASDAQ:INCR) is a publicly traded company in the Healthcare sector. Wiseek monitors INCR SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • InterCure's 2025 Revenue Jumps 13% to NIS 270M, Achieves Positive Operating Cash Flow
  • Intercure Faces Nasdaq Delisting Threat Amidst Major Lawsuits and Operational Challenges
  • InterCure receives Nasdaq delisting warning for minimum bid price non-compliance
  • InterCure Reports Strong Preliminary 2025 Results with 11% Revenue Growth, Positive EBITDA, and Significant Cash Inflow

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
270.2M
Net Income
-36.78M
Diluted EPS
-0.66
Op. Cash Flow
16.84M
Free Cash Flow
13.29M
Gross Profit
33.18M
Operating Income
-27.24M
Cash & Equivalents
45.23M
Total Debt
106.5M
Debt / Equity
0.27×
Net Margin
-13.6%
Source: 20-F · filed 2026-04-30 · accession 0001493152-26-020743

Insider Transactions

INCR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with I →
$0.8495 -0.02% today
52-week range · as of 2026-04-30 $0.68 – $1.77
Market cap
$47.79M
Volume
496.3K (11.0× avg)
3-mo avg 45.3K
Live data · 2026-06-14 05:16 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INCR - Latest Insights

INCR
Apr 30, 2026, 6:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
InterCure's 2025 Revenue Jumps 13% to NIS 270M, Achieves Positive Operating Cash Flow
Price at Filing: $0.840
Real-time Price: $0.8495 info
Change: +$0.0095 (+1%) info
Market Cap: $47.791M info
Sentiment: Positive
View Wiseek Article
INCR
Apr 30, 2026, 5:19 PM EDT
Filing Type: 20-F
Importance Score:
9
Intercure Faces Nasdaq Delisting Threat Amidst Major Lawsuits and Operational Challenges
Price at Filing: $0.840
Real-time Price: $0.8495 info
Change: +$0.0095 (+1%) info
Market Cap: $47.791M info
Sentiment: Negative
View Wiseek Article
INCR
Mar 03, 2026, 5:00 PM EST
Filing Type: 6-K
Importance Score:
8
InterCure receives Nasdaq delisting warning for minimum bid price non-compliance
Price at Filing: $0.8301
Real-time Price: $0.8495 info
Change: +$0.0194 (+2%) info
Market Cap: $47.791M info
Sentiment: Negative
View Wiseek Article
INCR
Feb 19, 2026, 7:35 AM EST
Filing Type: 6-K
Importance Score:
8
InterCure Reports Strong Preliminary 2025 Results with 11% Revenue Growth, Positive EBITDA, and Significant Cash Inflow
Price at Filing: $0.900
Real-time Price: $0.8495 info
Change: -$0.0505 (-6%) info
Market Cap: $47.791M info
Sentiment: Positive
View Wiseek Article